TEST:

Immune Profile Score Algorithmic Test

"Tempus AI...announced the clinical launch of its Immune Profile Score (IPS) algorithmic test. IPS, which is now available for clinicians to order, is a multimodal biomarker that can be used as a prognostic indicator for adult patients with stage IV and metastatic pan-solid tumors who are already considered candidates for immune checkpoint inhibitor (ICI)-based therapy. Tempus is presenting the results of its validation study at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting, which demonstrated that IPS-High patients in the study were more likely to have an overall survival benefit while receiving ICI-based therapy than IPS-Low patients in the study (HR 0.45). Tempus validated IPS in a retrospective study involving 1,600 metastatic and/or stage IV adult patients with 19 different solid tumor types from the company’s real-world de-identified database."